Skip to main content

Menopause clinical trials at UCSF
1 in progress, 1 open to new patients

  • A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis

    open to eligible females ages 18–62

    Duavee is a hormone receptor modulator that has been approved for the treatment of menopausal symptoms in menopausal women. The goal of this 8-week randomized, double blind, placebo controlled pilot study, is to determine whether this medication alleviates menopausal symptoms in women with MS. The investigators will secondarily determine whether addressing menopausal symptoms ameliorates MS symptoms and, on MRIs, is not triggering worsening inflammation.

    San Francisco, California